Name in SEC filings: Spyre Therapeutics, Inc.
Source: ORION, orionbiotechai.com/company/SYRE, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/SYRE
SPY072 · Topline/data readout · fourth quarter of 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutfourth quarter of 2026
Stage: Not stated
Public float: $1,100,000,000 · as of · SEC filing
axSpA sub-study: Double-blind, placebo-controlled safety and efficacy study of a single dose level of SPY072 at Week 16 with open-label follow-up through Week 40. Topline proof-of-concept data are expected in the fourth quarter of 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutfourth quarter of 2026
Stage: Not stated
Public float: $1,100,000,000 · as of · SEC filing
PsA sub-study: Double-blind, placebo-controlled safety and efficacy study of a single dose level of SPY072 at Week 16 with open-label follow-up through Week 40. Topline proof-of-concept data are expected in the fourth quarter of 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout2027
Stage: Not stated
Public float: $1,100,000,000 · as of · SEC filing
Topline induction data from Part B are expected in 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| SPY001 / SPY002 / SPY003 and pairwise combinationsClinical results | 2027“Topline induction data from Part B are expected in 2027.” Filed · 8-K | Period not started The stated period has not started yet, so there is nothing to compare. |
| SPY072Clinical results | fourth quarter of 2026“axSpA sub-study: Double-blind, placebo-controlled safety and efficacy study of a single dose level of SPY072 at Week 16 with open-label follow-up through Week 40. Topline proof-of-concept data are expected in the fourth quarter of 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| SPY072Clinical results | fourth quarter of 2026“PsA sub-study: Double-blind, placebo-controlled safety and efficacy study of a single dose level of SPY072 at Week 16 with open-label follow-up through Week 40. Topline proof-of-concept data are expected in the fourth quarter of 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| SPY001 / SPY002 / SPY003 and pairwise combinationsClinical results | 2027“Part B induction data (all cohorts) remain on track for 2027.” Filed · 8-K | Period not started The stated period has not started yet, so there is nothing to compare. |
| SPY001 / SPY002 / SPY003 and pairwise combinationsClinical results | 2027“Part B induction data (all cohorts) remain on track for 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for SYRE. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See SYRE in the calendar · Review labels and methodology